Alterations in tau proteostasis leading to detrimental loss-of-function effects have been shown in Alzheimer’s disease and related tauopathies where pathogenic tau alters nucleocytoplasmic transport by interacting with components of the nuclear pore complex (Eftekharzadeh et al., 2018). The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.